United States · Exchanges & live quotes · Nasdaq

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Published by Nasdaq · United States 2 h ago

Key PointsAlyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise.

Read the full article on Nasdaq Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.nasdaq.com)

Also worth reading

Africa Launches Its Own Oil Bank as Western Lenders Retreat

I Bonds Now Pay 5.51%—With a Long-Term Perk Savers Haven’t Seen in Decades

Animoca Brands Wins Abu Dhabi Approval to Manage Investment Funds

Rep. Haley Stevens speaks with Anderson Cooper on endorsement of GOP Mike Rogers

Cboe Global Markets

Nasdaq and S&P 500 Index Lose Momentum, Pull Down Market

Grounding agents in one context graph connecting semantic models you already trust